? SHARED RESOURCES MANAGEMENT The Ohio State University Comprehensive Cancer Center (OSUCCC) manages and supports 16 CCSG-funded Shared Resources (SRs) and is proposing two developing shared resources in this application. The goals of the OSUCCC SRs are to support OSUCCC members by providing specialized technologies, services, and expertise that maximize quality and speed of service, while maintaining cost-effectiveness and quality control. The SRs support all five Research Programs and are managed by faculty from seven different colleges and Nationwide Children?s Hospital. Most of the SRs are centrally located and in close proximity to OSUCCC members.
The Specific Aims for Shared Resource Management are to: 1) evaluate for need, and establish new specialized technologies, services and expertise that enhance scientific interaction and productivity; 2) ensure that the SRs provide cost-effective, reliable, and quality-controlled technologies, services and expertise; 3) support SRs through budget planning, laboratory management systems, and sustainability; and 4) establish policies for SR access and use. The OSUCCC directly manages 13 of the 16 SRs, and the others are jointly managed as institutional SRs that follow NCI policies. Reporting to the OSUCCC Director, the SRs are led by Sharyn Baker, PharmD, PhD, Associate Director for Shared Resources. Dr. Baker works with Heather Hampel MS, LGC, Associate Director for Biospecimen Research for integration of biospecimen services with the SRs. Dr. Baker leads the Shared Resource Team Leader (SRTL) committee that oversees SR management and implementation of the scientific vision. The SRTL monitors quality and user satisfaction through user surveys and user committees. SR development and evaluation is provided to Dr. Baker from the Associate Directors Committee, Program Leaders, and the External Scientific Advisory Board. Shared Resource Management operations include ensuring compliance with OSUCCC policies (prioritization of use and access, budgets, billing, and quality control) and compliance with OSU Office of Research policies and the federal Uniform Guidance. For the evaluation of new instrumentation and services, Dr. Baker manages the Intramural Research Program (IRP) that provides external peer review of SR applications, evaluating scientific merit and planned usage ($3.4M awarded this grant cycle. Overall support to the SRs over the last grant cycle has been $18M, allowing for all of the SRs to have been enhanced and offer new services. Future plans for each SR are accounting for planned increased usage due to the OSUCCC strategic research priorities and planned recruitment. The OSUCCC provides over $9M in overall support of the SRs annually, The OSUCCC is requesting a total of $1,971,340 in CCSG funding, 8.9% of the total support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090000
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Schimizzi, Gregory V; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford) 20:332-339
Fu, Xinping; Tao, Lihua; Wang, Pin-Yi et al. (2018) Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget 9:21348-21358
Brewington, Beatrice Y; Shao, Yusra F; Davidorf, Fredrick H et al. (2018) Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol 12:925-934
Doogan, Nathan J; Cooper, Sarah; Quisenberry, Amanda J et al. (2018) The role of travel distance and price promotions in tobacco product purchase quantity. Health Place 51:151-157
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Oblinger, Janet L; Burns, Sarah S; Huang, Jie et al. (2018) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol 299:299-307
Shu, Yi; Yin, Hongran; Rajabi, Mehdi et al. (2018) RNA-based micelles: A novel platform for paclitaxel loading and delivery. J Control Release 276:17-29
Hu, Zhiwei; Shen, Rulong; Campbell, Amanda et al. (2018) Targeting Tissue Factor for Immunotherapy of Triple-Negative Breast Cancer Using a Second-Generation ICON. Cancer Immunol Res 6:671-684

Showing the most recent 10 out of 2602 publications